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Abstract Retinal levels of vascular endothelial growth factor
(VEGF) and pigment epithelium-derived factor (PEDF), an
angiogenic inhibitor, were measured and correlated with the
ischemia-induced retinal neovascularization in rats. The retinas
with neovascularization showed a 5-fold increase in VEGF while
2-fold decrease in PEDF, compared to the age-matched controls,
resulting in an increased VEGF/PEDF ratio. The time course of
the VEGF/PEDF ratio change correlated with the progression of
retinal neovascularization. Changes in the VEGF and PEDF
mRNAs preceded their protein level changes. These results
suggest that an unbalance between angiogenic stimulators and
inhibitors may contribute to retinal neovascularization. ß 2001
Federation of European Biochemical Societies. Published by
Elsevier Science B.V. All rights reserved.
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1. Introduction
Retinal neovascularization, abnormal formation of new ves-
sels from preexisting capillaries in the retina, is a common
complication of many ocular diseases, such as advanced dia-
betic retinopathy, some forms of age-related macular degen-
eration and retinopathy of prematurity (ROP) [1^3]. Neovas-
cularization can lead to ¢brosis and disruption of delicate
tissues required for vision and hemorrhage. It is a major cause
of blindness in industrialized countries and a¡ects millions of
people varying in age from infants to the elderly [2,4].
The underlying mechanism of the retinal neovascularization
is not well understood. In normal ocular tissues, angiogenic
homeostasis is controlled by the balance between angiogenic
stimulators, such as vascular endothelial growth factor
(VEGF), and angiogenic inhibitors, such as pigment epitheli-
um-derived factor (PEDF) [2,5,6]. The endogenous angiogenic
inhibitors are believed to be essential for maintaining the ho-
meostasis of angiogenesis in the retina [7]. In previous studies,
the expression and role of angiogenic stimulators in retinal
neovascularization have been well studied but the role of de-
creased angiogenic inhibitors in pathological retinal neovascu-
larization has not been revealed.
PEDF was initially identi¢ed as a potential neurotrophic
factor [8]. It shares high sequence homology with other serine
proteinase inhibitors (serpin) and behaves like a non-inhibi-
tory serpin [9,10]. It is expressed in multiple tissues and is
present in the interphotoreceptor matrix at a high concentra-
tion (250 nM) [11,12]. PEDF is also present in the vitreous
and aqueous humors [12,13]. Recently, PEDF was shown to
have potent anti-angiogenic activity as it speci¢cally inhibited
the migration of endothelial cells, an essential step in angio-
genesis [6]. It was shown that PEDF contributes to most of
the anti-angiogenic activity in the vitreous. Puri¢ed PEDF
displayed anti-angiogenesis activity in the cornea [6]. The ex-
pression of PEDF in the retina was up-regulated by hyperoxia
in the retina of a mouse model. In a cultured retinoblastoma
cell line, PEDF was down-regulated by hypoxia [6]. The reg-
ulation of the PEDF expression by oxygen seemed to occur at
the protein level [6]. These ¢ndings suggest that PEDF may be
a key coordinator of retinal neuronal and vascular functions
and may have great therapeutic potential [14]. However, the
involvement of altered PEDF expression in pathological reti-
nal neovascularization has not been demonstrated.
In the present study, we have determined the PEDF expres-
sion in an ischemia-induced retinal neovascularization model
and correlated the VEGF/PEDF ratio with retinal neovascu-
larization.
2. Materials and methods
2.1. Animals
Brown Norway rats were purchased from Harlan (Indianapolis, IN,
USA). Care, use, and treatment of all animals in this study were in
strict agreement with the ARVO Statement for the Use of Animals in
Ophthalmic and Vision Research, as well as the guidelines set forth in
the Care and Use of Laboratory Animals by the Medical University
of South Carolina.
2.2. Oxygen-induced retinopathy
Retinal neovascularization was induced as described by Smith et al.
[15] with minor modi¢cations. Brie£y, newborn pigmented Brown
Norway rats were randomly assigned to the experimental and control
groups. At postnatal day 7 (P7), the rats in experimental group were
exposed to hyperoxia (75% O2) for 5 days (P7^12) and then returned
to normoxia (room air) to induce retinal neovascularization. Control
rats were kept at constant normoxia. At each of time points of P12,
P14, P16, P18, P20, P22 and P26, the retinas of three rats were dis-
sected and pooled for Western blot analysis, six rats for RNA prep-
aration and Northern blot analysis, two for eye ¢xation and section-
ing and two for £uorescein retinal angiography.
2.3. Retinal angiography with high molecular weight £uorescein
Animals were anesthetized and perfused with £uorescein via intra-
ventricle injection of 50 mg/ml of 2U106 molecular weight £uorescein
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isothiocyanate-dextran (Sigma) as described by Smith et al. [15]. The
animals were immediately killed. The eyes were enucleated and ¢xed
with 4% paraformaldehyde in phosphate-bu¡ered saline for 10 min.
The retina was then isolated from the eyecup and ¢xed with 4% para-
formaldehyde for 3 h. Several incisions were made to the retina. The
retina was £at-mounted on a gelatin-coated slide. The vasculature was
then examined under a £uorescent microscope (Axioplan2 Imaging,
Zeiss). To con¢rm pathological retinal neovascularization, eyes were
¢xed with 10% formaldehyde, sectioned and then stained with hema-
toxylin and eosin. The preretinal vascular cells were examined under a
light microscope.
2.4. Generation and puri¢cation of PEDF antibody
A polyclonal anti-PEDF antibody was raised in rabbits using a
PEDF-speci¢c peptide TSEFIHDIDRELKT. This peptide epitope
was chosen due to its high antigenicity index when analyzed by the
GCG program. The peptide was conjugated with keyhole limpet he-
macyanin (KLH) protein. Two female New Zealand White rabbits
were subcutaneously injected with an emulsion of 0.3 mg of the pep-
tide-KLH and Complete Freund’s Adjuvant (Gibco-BRL) and intra-
muscularly boosted with 0.3 mg of the same emulsion in 3-week
intervals. After good immune responses were developed, the rabbits
were killed and the whole serum was collected.
AminoLink Immobilization kit (Pierce) was used to purify the anti-
body speci¢c to the PEDF epitope. The PEDF epitope was dissolved
1 mg/ml in coupling bu¡er, and added at a 1:1 ratio to the Amino-
Link gel slurry with the addition of 200 Wl reductant. The gel slurry
was rocked end-over-end overnight at 4‡C and then drained. The
remaining active sites were blocked by washing with the quenching
bu¡er, and the immunized serum was loaded onto the column. The
anti-PEDF antibody was eluted by eight bed-volumes of the elution
bu¡er.
2.5. Western blot analysis
The retinas were dissected, pooled and homogenized by sonication.
The insoluble pellet was removed by centrifugation, and the protein
concentration of the supernatant was measured with the Bio-Rad
protein assay. 100 Wg of soluble proteins were resolved by SDS^
PAGE (12% polyacrylamide gel for PEDF, 15% polyacrylamide gel
for VEGF) and electro-transferred to Hybond ECL nitrocellulose
membrane (Amersham International plc). The membrane was then
blocked with 5% BLOTTO solution in TBST bu¡er (20 mM Tris^
Cl, pH 7.6, 137 mM NaCl, 0.1% Tween 20) with shaking for 1 h at
room temperature. The primary antibody (1:500 for both a monoclo-
nal antibody of VEGF from Santa Cruz, CA, USA, and the PEDF
antibody) was added to the BLOTTO and incubated with the mem-
brane overnight at 4‡C with shaking. The membrane was washed
three times with TBST at room temperature, 20 min each. An anti-
rabbit or anti-mouse IgG antibody labeled with horseradish peroxi-
dase (Vector International plc) was diluted 1:10 000 in the BLOTTO
solution and incubated with the membrane for 2 h at room temper-
ature. The membrane was washed three times with TBST. The bands
were visualized using the ECL detection kit (Amersham International
plc) and exposed to a Kodak X-Omat ¢lm. The same membrane was
stripped and re-blotted with an antibody speci¢c to L-actin (Sigma,
1:5000 dilution). Bands of VEGF and PEDF were semi-quanti¢ed by
densitometry using the Scanimage software and normalized by L-actin
levels.
2.6. Northern blot analysis
Retinas from each group were dissected and pooled for RNA iso-
lation. Total RNA was isolated from the retinas using Trizol reagents
(Gibco-BRL Life Technologies) according to the protocol recom-
mended by the manufacturer. 15 Wg of total RNA from each sample
was resolved on a 1.2% agarose gel, and transferred overnight to a
Nylon membrane (Amersham Life Science). After crosslinking, the
blot was prehybridized with Ultrahyb solution (Ambion) for 30 min
at 42‡C. VEGF and PEDF cDNAs were ampli¢ed by PCR from a rat
retina cDNA library and cloned. The cDNAs were labeled with
[K-32P]dCTP using the Nick Translation kit (Gibco-BRL). Hybridiza-
tion was carried out in the Ultrahyb solution (Ambion, Inc., Austin,
TX, USA) according to the manufacturer’s protocol. After hybridiza-
tion, the blot was washed twice for 5 min each with 2USSC, 0.1%
SDS in DEPC-H2O, followed by two 15 min washes with 0.1USSC,
0.1% SDS. The blot was exposed to Kodak X-Omat ¢lm and quanti-
¢ed by densitometry. After hybridization with the PEDF cDNA
probe, the RNA blot was stripped to remove the probe and re-probed
with the VEGF cDNA, and again with a labeled oligonucleotide
speci¢c to 18S RNA to normalize the loading. The RNA levels
were semi-quanti¢ed by densitometry and normalized by 18S RNA
levels. For each analysis, two independent experiments were per-
formed and results averaged.
3. Results
3.1. Time course of hyperoxia-induced retinopathy in
Brown Norway rats
Rats at P7 were exposed to hyperoxia for 5 days and then
returned to normoxia at P12. The retinal vasculature was
examined by £uorescein-dextran retinal angiography between
P12 and P22. As shown in Fig. 1, the retinas from control rats
between P12 and P22 developed both super¢cial and deep
vascular layers that extended from the optic disc to the pe-
riphery. The vessels formed a ¢ne radial branching pattern in
the super¢cial retinal layer and a polygonal reticular pattern
in the deep retinal layer (Figs. 1 and 2A). Small, non-perfused
areas were observed only at an early stage (P12) (Fig. 1, C/
P12). At later stages (P18^P22), the non-perfusion area dis-
appeared and a mature capillary network formed an arboriz-
ing pattern (Fig. 1, C/P14^C/P22). This time course of retinal
vascular development in Brown Norway rats was similar to
that observed in the newborn mouse [15].
In hyperoxia-treated rats at P12 (0 day after the return
from hyperoxia to normoxia), large areas of the central retina
showed almost no capillaries, and only small perfusion areas
were visible in the peripheral retina (Fig. 1, H/P12). From P14
(2 days after the return) to P22 (10 days after the return), the
central hypoperfusion areas were progressively decreased and
the radial vessels appeared tortuous and dilated (Fig. 1, H/
P14^H/P22). The neovascular tufts, non-perfusion regions,
microaneurism and hemorrhage that represent a typical pat-
tern of pathological retinal neovascularization were observed
in all of the hyperoxia-treated rats at P14^P22 (Figs. 1 and 2).
These results demonstrated that retinal vasculature develop-
ment was inhibited by exposure to hyperoxia and the neo-
vascularization began at P14, 2 days after the rats were re-
turned from hyperoxia to normoxia, and progressed from P14
to P22.
3.2. Negative correlation between PEDF levels and retinal
neovascularization
To determine if endogenous angiogenic inhibitors are in-
volved in ischemia-induced retinal neovascularization, PEDF
was measured by Western blot analysis and normalized by L-
actin. At P12, after exposure to 75% O2 for 5 days, PEDF
protein levels were elevated by 3.8-fold over that in age-
matched controls (Fig. 3), which was consistent with the im-
munostaining result in the mouse model [6]. In contrast, at
age P14 and P16 (2 and 4 days after the return from hyper-
oxia), the protein levels of PEDF decreased to 84% and 51%
of respective control levels (Fig. 3). The lowest PEDF level
was observed at P16 when the most aggressive progression of
retinal neovascularization occurred (Fig. 1). After P18, PEDF
levels began to recover gradually. When retinal neovasculari-
zation was essentially complete at P22 and P26, PEDF was
brought to the control level. These results demonstrated that
retinal PEDF levels are negatively correlated with the progres-
sion of neovascularization.
FEBS 24560 25-1-01 Cyaan Magenta Geel Zwart
G. Gao et al./FEBS Letters 489 (2001) 270^276 271
FEBS 24560 25-1-01 Cyaan Magenta Geel Zwart
G. Gao et al./FEBS Letters 489 (2001) 270^276272
3.3. Positive correlation between VEGF levels and retinal
neovascularization
At P12, after exposure to 75% O2 for 5 days, the protein
level of VEGF was reduced by 3-fold, compared to age-
matched controls, in contrast to the increased PEDF levels
(Fig. 4). From P14 to P16, 2 and 4 days after hyperoxia treat-
ment, VEGF started to increase to levels higher than controls.
The highest VEGF levels were found at P16 (500% of the
control level), 4 days after the animals were returned to nor-
moxia from hyperoxia. VEGF levels gradually dropped from
P18 to P26 to approximate normal level. This time course of
VEGF expression change was positively correlated with the
onset and progression of retinal neovascularization.
3.4. Increased VEGF/PEDF ratio in the ischemia-induced
retinopathy
As shown in Figs. 3 and 4, the most apparent changes in
VEGF and PEDF levels occurred at the same time points but
toward opposite directions. To determine the balance between
VEGF and PEDF in angiogenesis regulation, the relative
VEGF/PEDF ratio was calculated at each time point analyzed
(Fig. 5). At P12, exposure to 5 days of hyperoxia up-regulated
PEDF and down-regulated VEGF, resulting in the lowest
VEGF/PEDF ratio. The lower ratio may account for the en-
larged non-perfusion region in the retinas of hyperoxia-
treated rats (Fig. 1). In the period from P12 to P16, the ratio
increased from less than 1 up to 10 at the peak of P16. Con-
sistently, most aggressive progression of neovascularization
was observed during this period. After P18, the ratio remained
higher than the control but gradually decreased to the control
level at P26, when neovascularization was essentially com-
plete.
Fig. 2. Ischemia-induced retinopathy in rats. A and B: Control animals (P18) maintained in constant normoxia; C and D: newborn rats were
exposed to 5 days of hyperoxia followed by 6 days of normoxia (P18). Retinas from oxygen-treated animals showed vessel dilation and neovas-
cular tufts (C, 100U) and hemorrhage (D, 200U) which are not present in age-matched normal controls (A, 100U and B, 200U).
Fig. 1. Time course of ischemia-induced retinal neovascularization in rats. Brown Norway rats at P7 were exposed to hyperoxia for 5 days and
then returned to normoxia (indicated by H). Age-matched rats kept in constant normoxia were used as normal controls (indicated by C). Fluo-
rescein retinal angiography was performed at each of the following time points: P12, P14, P18 and P22. Note the enlarged non-perfusion areas
in oxygen-treated rats at P12 and progressive retinal neovascularization from P14 to P22 (12.5U).
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3.5. Changes of PEDF and VEGF mRNA in the retinal
neovascularization model
Northern blot analysis demonstrated that the expression
changes of PEDF occurred at the RNA level in the retinal
neovascularization model. The changes in the PEDF mRNA
level were detected prior to that of the protein level. The
decreased PEDF mRNA was detected as early as P12 when
the animals were just returned to normoxia. The lowest PEDF
RNA level (approximately 50% of the control level) was ob-
served at P14, 2 days before that of protein. The PEDF
mRNA recovered to the control level after P16 (Fig. 6).
Consistent with previous observations in the mouse model
[16], VEGF expression changes were also detected at the
mRNA level in this rat model. The VEGF mRNA increase
preceded that of the protein level (Fig. 7). The VEGF mRNA
started to increase at P12 while the earliest increase of the
Fig. 3. PEDF levels in the retina during the development of neovas-
cularization. (A) Western blot analysis of PEDF: retinas from three
oxygen-treated (lanes indicated by H) and age-matched normal con-
trol rats (indicated by C) were dissected at each of the time points
as indicated. The retinas of each group were pooled and homoge-
nized. The same amount (100 Wg) of soluble protein from each
group was blotted with a speci¢c anti-PEDF antibody. (B) The
same membrane from (A) was stripped and re-blotted with an anti-
body speci¢c to L-actin. The bands were semi-quanti¢ed with densi-
tometry. PEDF protein levels were normalized by the L-actin signal
at the same time points. Ratios of PEDF in hyperoxia-treated ani-
mals to the age-matched controls at each time point were calculated
and plotted (mean þ S.E.M., n = 2) (C).
Fig. 4. VEGF levels in the retina during the development of neovas-
cularization. (A) Western blot analysis of VEGF: retinas from the
same oxygen-treated (indicated by H) and control (indicated by C)
rats as those in Fig. 3 were pooled, and 100 Wg of soluble proteins
were blotted with an antibody speci¢c to VEGF. (B) The same
membrane was re-blotted with the anti-L-actin antibody. The bands
were quanti¢ed by densitometry, normalized by L-actin. The average
ratios (mean þ S.E.M., n = 2) of VEGF in hyperoxia-treated animals
to controls were calculated at the time points as indicated (C).
Fig. 5. Retinal VEGF/PEDF ratios in the development of neovascu-
larization. The VEGF and PEDF levels at each time point were ¢rst
normalized by L-actin to exclude artifacts. The normalized VEGF/
PEDF ratio at the time point was calculated as the following: the
normalized VEGF level in a hyperoxia-treated group was divided
by the PEDF level in the same group to obtain the VEGF/PEDF
value in the hyperoxia-treated group. Similarly, VEGF/PEDF ratio
in the control group was calculated. The VEGF/PEDF ratio in the
hyperoxia-treated group was divided by the VEGF/PEDF in the
control group at the same time point to obtain the normalized ra-
tio.
Fig. 6. PEDF mRNA levels in the retina with neovascularization.
The same amounts of total RNA from hyperoxia-treated (indicated
by H) and control groups (indicated by C) at various ages were
used for Northern blot analysis using a PEDF cDNA probe (A)
and a 18S ribosomal RNA probe (B). The levels were quanti¢ed by
densitometry and normalized by 18S ribosomal RNA levels. The ra-
tios (mean þ S.E.M., n = 2) of PEDF mRNA in hyperoxia-treated
animals to that of respective controls were calculated at each time
point (C).
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protein level was observed at P14. The peak of the mRNA
level (approximately 250% of the control level) was observed
at P14, 2 days before the peak of the protein (P16).
4. Discussion
PEDF is a potent angiogenic inhibitor endogenously ex-
pressed in the retina [6]. However, its role in pathological
neovascularization has not been revealed previously. The
present study demonstrated for the ¢rst time that the retinal
PEDF levels, in contrast to that of VEGF, are negatively
correlated with pathological retinal neovascularization. The
decreased PEDF level may contribute to the development of
retinal neovascularization in the ischemia-induced retinopathy
model. This ¢nding further con¢rms the function of PEDF as
an angiogenic inhibitor which is involved in the pathogenesis
of retinal neovascularization.
It is believed that homeostasis of angiogenesis is regulated
by two counter-balancing systems: angiogenic stimulators and
angiogenic inhibitors. This balance is critical for the regula-
tion of angiogenesis [2,5]. Under pathological conditions such
as diabetic retinopathy and ROP, regions of the retina become
hypoxic due to blood vessel abnormalities and modi¢cation of
hemoglobin. It is hypothesized that in response to hypoxia,
the retina increases the production of angiogenic stimulators
and reduces the production of angiogenic inhibitors, disturb-
ing the balance between the positive and negative regulators
of angiogenesis [2]. As a result, endothelial cells over-prolifer-
ate, leading to retinal neovascularization [2,6]. Our studies
demonstrate an increased VEGF and decreased PEDF in
the ischemia-induced retinal neovascularization rat model, re-
sulting in a higher VEGF/PEDF ratio. The time course of the
PEDF down-regulation is consistent with the increased VEGF
expression, i.e. the highest VEGF levels coincide with the low-
est PEDF levels (Fig. 4). The opposite changes of VEGF and
PEDF magnify the change in the angiogenic stimulator/inhib-
itor ratio. Moreover, the time course of the VEGF/PEDF
ratio change is correlated with the development and progres-
sion of retinal neovascularization. These results provide evi-
dence supporting the hypothesis that a broken balance be-
tween angiogenic stimulators and inhibitors is a cause of
pathological retinal neovascularization, at least in this animal
model.
The normal vitreous body is known to contain multiple
angiogenic inhibitors, including TGF-L [17], PEDF [6] and
angiostatin (unpublished result). These inhibitors are believed
to play a critical role in maintaining the avascular status of
the vitreous. Under certain pathological conditions such as
diabetic retinopathy and ROP, decreased expression of these
inhibitors may weaken the inhibition of angiogenesis, result-
ing in over-proliferation of endothelial cells and consequently
pathological neovascularization. Therefore, restoration of the
balance between the angiogenic stimulators and inhibitors by
provision of endogenous angiogenic inhibitors can become a
potential therapeutic strategy to arrest the progression of ret-
inal neovascularization. Identi¢cation of endogenous angio-
genic inhibitors that are down-regulated in pathological reti-
nal neovascularization may reveal the candidates for anti-
angiogenic therapy using endogenous inhibitors and will con-
tribute to the development of a new anti-angiogenic therapy.
It is well-known that regulation of VEGF by hypoxia oc-
curs at the transcriptional level via the hypoxia-induced factor
pathway [18]. The present study detected the change of VEGF
mRNA in the retinal neovascularization rat model, which is
consistent with previous ¢ndings in the mouse model [16].
However, the regulatory mechanism of PEDF expression is
presently uncertain. It has been shown that down-regulation
of PEDF expression by hypoxia occurs at the protein level in
a cultured retinoblastoma cell line [6]. However, Coljee et al.
reported that regulation of PEDF expression occurs at the
hnRNA level in ¢broblast cells [19]. Consistent with the latter
report, our Northern blot analysis using whole retinal RNA
detected a decreased PEDF mRNA level in the retina with
pathological neovascularization. Moreover, the PEDF RNA
decrease is approximately to the same extent as, but precedes
the protein level change. These results seem to support a reg-
ulation at the RNA level. The disparity between our results
and the previous studies by Dawson et al. [6] could be as-
cribed to that we used an animal model rather than a hypoxic
cell culture which are in di¡erent environments. The retina
consists of multiple cell types which may have a PEDF regu-
latory mechanism di¡erent from the transformed cell line.
Most diabetic mouse and rat models do not develop typical
proliferative retinopathy [20]. The ischemia-induced retinal
neovascularization model closely resembles ROP. As retinal
hypoxia is the direct cause and increased VEGF is a major
mediator of neovascularization, the pathological mechanism
of this model is similar to that of human diabetic retinopathy.
Therefore, this model is also considered an accepted model for
diabetic retinopathy [16]. Previous studies have shown that
compared to mice, rats are less prone to develop ischemia-
induced retinal neovascularization, and require cycling be-
tween hypoxia and normoxia to develop signi¢cant retinal
neovascularization [21,22]. However, most of these previous
studies used Sprague Dawley rats [22,23]. For a reason yet to
be revealed, we found that pigmented Brown Norway rats are
much more sensitive to the hyperoxia treatment and more
prone to develop retinal neovascularization, compared to
Sprague Dawley rats under the same conditions (unpublished
data). Similar to the mouse model, it only requires an expo-
sure to constant hyperoxia for 5 days followed by constant
Fig. 7. VEGF mRNA levels in the retina with neovascularization.
The Northern blot ¢lter for PEDF was stripped and re-probed with
the VEGF cDNA (A) and normalized by 18S ribosomal RNA (B).
The ratios (mean þ S.E.M., n = 2) of VEGF in hyperoxia-treated ani-
mals to that in respective controls were calculated at each time
point (C).
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normoxia to induce signi¢cant retinal neovascularization.
Moreover, the vascular abnormalities in the Brown Norway
rat model are similar to those in human diabetic retinopathy
and to the mouse model (Figs. 1 and 2). Because of the larger
size of the rat eye compared to the mouse, the Brown Norway
rat model will be convenient for intravitreal delivery of ther-
apeutic reagents for the treatment of retinal neovasculariza-
tion.
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